Iguratimod found Effective in Rheumatoid Arthritis without MTX or bDMARDs as well as in Combination with MTX

Primary tabs

NEWS
Iguratimod found Effective in Rheumatoid Arthritis without MTX or bDMARDs as well as in Combination with MTX

The scientists of Gunma University Graduate School of Medicine elucidates that Iguratimod either with Methotrexate/bDMARDs or without it shows significant efficacy in managing rheumatoid arthritis (RA). Iguratimod (IGU) is a DMARD which inhibits the activation of various inflammatory cytokines and immunoglobulins.

This analysis involved 69 patients who were categorized into three groups: IGU, IGU + Methotrexate (MTX) and IGU + bDMARDs. The clinical course and baseline features were assessed for more than three years. A statistical analysis of predictive factors related to the attainment of low disease activity (LDA) was also done.

A total 40.6% survival rate was seen for IGU therapy at 3-year assessment. The IGU and IGU + MTX showed a significantly reduced disease activity as compared to baseline. At three years, 38 patients were attained LDA. The factors that significantly correlated with achieving low disease activity were no use of Prednisolone (PSL), low DAS28-CRP and patients gender (women). These outcomes reflected that IGU alone or in combination with MTX shows considerable effectiveness in gaining LDA among RA patients.

Source

Modern Rheumatology 

the source:

https://www.tandfonline.com/doi/abs/10.1080/14397595.2018.1510879

Original title of the article:

The three-year efficacy of Iguratimod in clinical daily practice in patients with rheumatoid arthritis

Authors:

Takahito Suto et al.

SearchTags: 
Therapeutic, Iguratimod, Rheumatoid Arthritis, Joints, DMARD, Efficacy, LDA, DAS28-CRP
Log in or register to post comments